Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

Biotech ETFs offer diversified exposure to the sector, reducing investment risk. Investing in top biotech ETFs can be cost-effective due to their low expense ratios. Large biotech ETFs provide better ...

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion of the S&P 500, started in January ...

The Invesco Biotechnology & Genome ETF (PBE) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the ...

State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Biotech ETF BBC hits a 52-week high, likely fueled by strong clinical trial results and rising M&A activity, and renewed risk-on sentiment.

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...